U.S. flag

An official website of the United States government

NM_000525.4(KCNJ11):c.497G>T (p.Cys166Phe) AND Glibenclamide response

Germline classification:
drug response (1 submission)
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002247280.1

Allele description [Variation Report for NM_000525.4(KCNJ11):c.497G>T (p.Cys166Phe)]

NM_000525.4(KCNJ11):c.497G>T (p.Cys166Phe)

Gene:
KCNJ11:potassium inwardly rectifying channel subfamily J member 11 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
11p15.1
Genomic location:
Preferred name:
NM_000525.4(KCNJ11):c.497G>T (p.Cys166Phe)
HGVS:
  • NC_000011.10:g.17387595C>A
  • NG_012446.1:g.6065G>T
  • NM_000525.4:c.497G>TMANE SELECT
  • NM_001166290.2:c.236G>T
  • NM_001377296.1:c.236G>T
  • NM_001377297.1:c.236G>T
  • NP_000516.3:p.Cys166Phe
  • NP_000516.3:p.Cys166Phe
  • NP_001159762.1:p.Cys79Phe
  • NP_001364225.1:p.Cys79Phe
  • NP_001364226.1:p.Cys79Phe
  • NC_000011.9:g.17409142C>A
  • NM_000525.3:c.497G>T
Protein change:
C166F; CYS166PHE
Links:
OMIM: 600937.0015; dbSNP: rs80356618
NCBI 1000 Genomes Browser:
rs80356618
Molecular consequence:
  • NM_000525.4:c.497G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001166290.2:c.236G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001377296.1:c.236G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001377297.1:c.236G>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Glibenclamide response
Synonyms:
Glyburide response; Glybenclamide response
Identifiers:
MedGen: CN437679

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002512141Clinical Genomics, Uppaluri K&H Personalized Medicine Clinic
criteria provided, single submitter

(K & H Uppaluri Personalized Medicine Clinic Variant Classification & Assertion Criteria_Updated V.1)
drug response
Condition: glibenclamide response
somaticresearch

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedsomaticyesnot providednot providednot providednot providednot providedresearch

Details of each submission

From Clinical Genomics, Uppaluri K&H Personalized Medicine Clinic, SCV002512141.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providedresearchnot provided

Description

Mutations in KCNJ11 gene can cause decreased production and secretion of insulin. This can lead to MODY which may be responsive to oral sulfonylureas. However, this particular variant rs80356618 is associated with poor response to glibenclamide.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1somaticyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 8, 2022